Jeil Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio
Jeil Pharmaceutical Co Ltd cash flow-to-debt ratio. Jeil Pharmaceutical Co Ltd (271980) has a Cash Flow-to-Debt Ratio of -0.03x as of June 2026, meaning its operating cash flow of ₩-9.47 Billion could theoretically repay 0% of its total liabilities (₩272.85 Billion) in one year. Check 271980 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Jeil Pharmaceutical Co Ltd (2017–2025)
Cash flow-to-debt ratio of Jeil Pharmaceutical Co Ltd from 2017 to 2025. Historical debt coverage capacity for Jeil Pharmaceutical Co Ltd across 9 annual periods. Check total reinvestment intensity of Jeil Pharmaceutical Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
Jeil Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio by Year (2017–2025)
Jeil Pharmaceutical Co Ltd cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for Jeil Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see cash flow conversion of Jeil Pharmaceutical Co Ltd.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.02x | ₩-5.69 Billion | ₩259.55 Billion | ▼ -309.0% |
| 2024 | 0.01x | ₩3.21 Billion | ₩306.38 Billion | ▲ +169.5% |
| 2023 | -0.02x | ₩-4.98 Billion | ₩330.29 Billion | ▲ +70.0% |
| 2022 | -0.05x | ₩-15.15 Billion | ₩301.29 Billion | ▼ -168.2% |
| 2021 | 0.07x | ₩19.10 Billion | ₩259.14 Billion | ▲ +191.8% |
| 2020 | -0.08x | ₩-19.05 Billion | ₩237.18 Billion | ▼ -164.2% |
| 2019 | 0.13x | ₩28.96 Billion | ₩231.54 Billion | ▲ +27.1% |
| 2018 | 0.10x | ₩21.45 Billion | ₩217.97 Billion | ▲ +651.2% |
| 2017 | -0.02x | ₩-4.21 Billion | ₩235.74 Billion | — |